Does the media refer more to TFX or TNDM?

In the previous week, Teleflex had 3 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 8 mentions for Teleflex and 5 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.49 beat Teleflex's score of 1.10 indicating that Tandem Diabetes Care is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teleflex 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tandem Diabetes Care 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MMED or TNDM?

In the previous week, Tandem Diabetes Care had 4 more articles in the media than MiniMed Group. MarketBeat recorded 5 mentions for Tandem Diabetes Care and 1 mentions for MiniMed Group. Tandem Diabetes Care's average media sentiment score of 1.49 beat MiniMed Group's score of 0.00 indicating that Tandem Diabetes Care is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiniMed Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tandem Diabetes Care 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LIVN or TNDM?

In the previous week, Tandem Diabetes Care had 1 more articles in the media than LivaNova. MarketBeat recorded 5 mentions for Tandem Diabetes Care and 4 mentions for LivaNova. Tandem Diabetes Care's average media sentiment score of 1.49 beat LivaNova's score of 0.14 indicating that Tandem Diabetes Care is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tandem Diabetes Care 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ITGR or TNDM?

In the previous week, Integer had 3 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 8 mentions for Integer and 5 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.49 beat Integer's score of 1.42 indicating that Tandem Diabetes Care is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Integer 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tandem Diabetes Care 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IRTC or TNDM?

In the previous week, iRhythm Technologies had 1 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 6 mentions for iRhythm Technologies and 5 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.49 beat iRhythm Technologies' score of 0.28 indicating that Tandem Diabetes Care is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRhythm Technologies 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tandem Diabetes Care 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tandem Diabetes Care (TNDM) Competitors

$22.32 -0.25 (-1.11%)

As of 08/21/2026 04:00 PM Eastern

Compare

TNDM vs. TFX, MMED, LIVN, ITGR, and IRTC

Should you buy Tandem Diabetes Care stock or one of its competitors? Tandem Diabetes Care's main competitors and comparable companies include Teleflex (TFX), MiniMed Group (MMED), LivaNova (LIVN), Integer (ITGR), and iRhythm Technologies (IRTC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Tandem Diabetes Care compare to Teleflex?

Teleflex (NYSE:TFX) and Tandem Diabetes Care (NASDAQ:TNDM) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

Tandem Diabetes Care has a net margin of -6.08% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teleflex	-39.67%	11.93%	5.44%
Tandem Diabetes Care	-6.08%	-45.97%	-6.23%

Teleflex currently has a consensus price target of $151.80, suggesting a potential upside of 9.22%. Tandem Diabetes Care has a consensus price target of $28.98, suggesting a potential upside of 29.82%. Given Tandem Diabetes Care's stronger consensus rating and higher possible upside, analysts clearly believe Tandem Diabetes Care is more favorable than Teleflex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teleflex	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42
Tandem Diabetes Care	1 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.48

Tandem Diabetes Care has lower revenue, but higher earnings than Teleflex. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teleflex	$1.99B	2.96	-$905.64M	-$23.29	N/A
Tandem Diabetes Care	$1.01B	1.53	-$204.71M	-$0.93	N/A

95.6% of Teleflex shares are owned by institutional investors. 0.7% of Teleflex shares are owned by company insiders. Comparatively, 2.1% of Tandem Diabetes Care shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Teleflex has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Tandem Diabetes Care has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market.

In the previous week, Teleflex had 3 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 8 mentions for Teleflex and 5 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.49 beat Teleflex's score of 1.10 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teleflex	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tandem Diabetes Care	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tandem Diabetes Care beats Teleflex on 9 of the 16 factors compared between the two stocks.

How does Tandem Diabetes Care compare to MiniMed Group?

MiniMed Group (NASDAQ:MMED) and Tandem Diabetes Care (NASDAQ:TNDM) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Tandem Diabetes Care has lower revenue, but higher earnings than MiniMed Group. MiniMed Group is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiniMed Group	$3.10B	1.85	-$333M	-$0.68	N/A
Tandem Diabetes Care	$1.01B	1.53	-$204.71M	-$0.93	N/A

In the previous week, Tandem Diabetes Care had 4 more articles in the media than MiniMed Group. MarketBeat recorded 5 mentions for Tandem Diabetes Care and 1 mentions for MiniMed Group. Tandem Diabetes Care's average media sentiment score of 1.49 beat MiniMed Group's score of 0.00 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiniMed Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tandem Diabetes Care	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MiniMed Group presently has a consensus target price of $21.62, suggesting a potential upside of 5.70%. Tandem Diabetes Care has a consensus target price of $28.98, suggesting a potential upside of 29.82%. Given Tandem Diabetes Care's higher possible upside, analysts plainly believe Tandem Diabetes Care is more favorable than MiniMed Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Tandem Diabetes Care	1 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.48

MiniMed Group has a net margin of 0.00% compared to Tandem Diabetes Care's net margin of -6.08%. MiniMed Group's return on equity of 0.00% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiniMed Group	N/A	N/A	N/A
Tandem Diabetes Care	-6.08%	-45.97%	-6.23%

Summary

MiniMed Group beats Tandem Diabetes Care on 8 of the 14 factors compared between the two stocks.

How does Tandem Diabetes Care compare to LivaNova?

LivaNova (NASDAQ:LIVN) and Tandem Diabetes Care (NASDAQ:TNDM) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

LivaNova currently has a consensus price target of $83.50, suggesting a potential upside of 6.05%. Tandem Diabetes Care has a consensus price target of $28.98, suggesting a potential upside of 29.82%. Given Tandem Diabetes Care's higher probable upside, analysts clearly believe Tandem Diabetes Care is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55
Tandem Diabetes Care	1 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.48

97.6% of LivaNova shares are owned by institutional investors. 0.4% of LivaNova shares are owned by company insiders. Comparatively, 2.1% of Tandem Diabetes Care shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Tandem Diabetes Care has lower revenue, but higher earnings than LivaNova. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.12	-$242.47M	$3.38	23.30
Tandem Diabetes Care	$1.01B	1.53	-$204.71M	-$0.93	N/A

In the previous week, Tandem Diabetes Care had 1 more articles in the media than LivaNova. MarketBeat recorded 5 mentions for Tandem Diabetes Care and 4 mentions for LivaNova. Tandem Diabetes Care's average media sentiment score of 1.49 beat LivaNova's score of 0.14 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tandem Diabetes Care	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LivaNova has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Tandem Diabetes Care has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market.

LivaNova has a net margin of 12.82% compared to Tandem Diabetes Care's net margin of -6.08%. LivaNova's return on equity of 16.35% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	12.82%	16.35%	7.76%
Tandem Diabetes Care	-6.08%	-45.97%	-6.23%

Summary

LivaNova beats Tandem Diabetes Care on 9 of the 17 factors compared between the two stocks.

How does Tandem Diabetes Care compare to Integer?

Integer (NYSE:ITGR) and Tandem Diabetes Care (NASDAQ:TNDM) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

In the previous week, Integer had 3 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 8 mentions for Integer and 5 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.49 beat Integer's score of 1.42 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integer	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tandem Diabetes Care	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Integer has higher revenue and earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.84B	2.31	$102.81M	$3.66	34.21
Tandem Diabetes Care	$1.01B	1.53	-$204.71M	-$0.93	N/A

Integer presently has a consensus target price of $109.86, indicating a potential downside of 12.27%. Tandem Diabetes Care has a consensus target price of $28.98, indicating a potential upside of 29.82%. Given Tandem Diabetes Care's stronger consensus rating and higher possible upside, analysts plainly believe Tandem Diabetes Care is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07
Tandem Diabetes Care	1 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.48

Integer has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, Tandem Diabetes Care has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market.

Integer has a net margin of 6.97% compared to Tandem Diabetes Care's net margin of -6.08%. Integer's return on equity of 12.79% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integer	6.97%	12.79%	6.48%
Tandem Diabetes Care	-6.08%	-45.97%	-6.23%

99.3% of Integer shares are held by institutional investors. 1.1% of Integer shares are held by insiders. Comparatively, 2.1% of Tandem Diabetes Care shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Integer beats Tandem Diabetes Care on 10 of the 17 factors compared between the two stocks.

How does Tandem Diabetes Care compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and Tandem Diabetes Care (NASDAQ:TNDM) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

In the previous week, iRhythm Technologies had 1 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 6 mentions for iRhythm Technologies and 5 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.49 beat iRhythm Technologies' score of 0.28 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tandem Diabetes Care	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iRhythm Technologies has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market. Comparatively, Tandem Diabetes Care has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market.

iRhythm Technologies has higher earnings, but lower revenue than Tandem Diabetes Care. iRhythm Technologies is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	5.67	-$44.55M	-$0.43	N/A
Tandem Diabetes Care	$1.01B	1.53	-$204.71M	-$0.93	N/A

iRhythm Technologies has a net margin of -1.69% compared to Tandem Diabetes Care's net margin of -6.08%. iRhythm Technologies' return on equity of 10.11% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-1.69%	10.11%	1.53%
Tandem Diabetes Care	-6.08%	-45.97%	-6.23%

iRhythm Technologies currently has a consensus price target of $179.93, indicating a potential upside of 40.00%. Tandem Diabetes Care has a consensus price target of $28.98, indicating a potential upside of 29.82%. Given iRhythm Technologies' stronger consensus rating and higher possible upside, research analysts plainly believe iRhythm Technologies is more favorable than Tandem Diabetes Care.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
Tandem Diabetes Care	1 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.48

Summary

iRhythm Technologies beats Tandem Diabetes Care on 11 of the 15 factors compared between the two stocks.

Get Tandem Diabetes Care News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNDM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNDM vs. The Competition

Export

Metric	Tandem Diabetes Care	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.55B	$6.02B	$7.37B	$12.85B
Dividend Yield	N/A	1.75%	2.53%	11.08%
P/E Ratio	-24.00	26.67	272.88	24.24
Price / Sales	1.53	45.38	618.96	99.81
Price / Cash	N/A	33.24	78.62	53.99
Price / Book	11.94	6.23	13.05	6.20
Net Income	-$204.71M	$150.07M	$3.47B	$348.59M
7 Day Performance	-1.76%	0.69%	2.09%	0.08%
1 Month Performance	32.07%	8.91%	6.64%	3.88%
1 Year Performance	87.09%	8.07%	25.02%	16.98%

Tandem Diabetes Care Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNDM Tandem Diabetes Care	3.3284 of 5 stars	$22.32 -1.1%	$28.98 +29.8%	+87.1%	$1.55B	$1.01B	N/A	2,500	Positive News Analyst Forecast
TFX Teleflex	3.7672 of 5 stars	$133.05 -3.0%	$151.80 +14.1%	+7.5%	$5.81B	$1.99B	N/A	15,500
MMED MiniMed Group	1.671 of 5 stars	$19.53 -3.1%	$21.62 +10.7%	N/A	$5.66B	$3.10B	N/A	2,800
LIVN LivaNova	2.4745 of 5 stars	$81.48 -0.9%	$83.50 +2.5%	+40.9%	$4.53B	$1.47B	24.11	3,300	Positive News Analyst Upgrade
ITGR Integer	2.6564 of 5 stars	$125.13 -0.1%	$109.86 -12.2%	+13.2%	$4.26B	$1.85B	34.19	11,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNDM) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tandem Diabetes Care (TNDM) Competitors

TNDM vs. TFX, MMED, LIVN, ITGR, and IRTC

How does Tandem Diabetes Care compare to Teleflex?

Summary

How does Tandem Diabetes Care compare to MiniMed Group?

Summary

How does Tandem Diabetes Care compare to LivaNova?

Summary

How does Tandem Diabetes Care compare to Integer?

Summary

How does Tandem Diabetes Care compare to iRhythm Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNDM vs. The Competition

Tandem Diabetes Care Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tandem Diabetes Care (TNDM) Competitors

TNDM vs. TFX, MMED, LIVN, ITGR, and IRTC

How does Tandem Diabetes Care compare to Teleflex?

Is TFX or TNDM more profitable?

Do analysts prefer TFX or TNDM?

Which has higher valuation and earnings, TFX or TNDM?

Do institutionals and insiders have more ownership in TFX or TNDM?

Which has more volatility & risk, TFX or TNDM?

Does the media refer more to TFX or TNDM?

Summary

How does Tandem Diabetes Care compare to MiniMed Group?

Which has preferable valuation & earnings, MMED or TNDM?

Does the media prefer MMED or TNDM?

Do analysts prefer MMED or TNDM?

Is MMED or TNDM more profitable?

Summary

How does Tandem Diabetes Care compare to LivaNova?

Do analysts prefer LIVN or TNDM?

Do insiders & institutionals have more ownership in LIVN or TNDM?

Which has stronger earnings and valuation, LIVN or TNDM?

Does the media prefer LIVN or TNDM?

Which has more risk & volatility, LIVN or TNDM?

Is LIVN or TNDM more profitable?

Summary

How does Tandem Diabetes Care compare to Integer?

Does the media prefer ITGR or TNDM?

Which has better earnings & valuation, ITGR or TNDM?

Do analysts prefer ITGR or TNDM?

Which has more risk & volatility, ITGR or TNDM?

Is ITGR or TNDM more profitable?

Do institutionals and insiders hold more shares of ITGR or TNDM?

Summary

How does Tandem Diabetes Care compare to iRhythm Technologies?

Does the media refer more to IRTC or TNDM?

Which has more risk and volatility, IRTC or TNDM?

Which has preferable valuation & earnings, IRTC or TNDM?

Is IRTC or TNDM more profitable?

Do analysts recommend IRTC or TNDM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNDM vs. The Competition

Tandem Diabetes Care Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools